Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization:A retrospective comparative study

摘要

AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE)treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage[Barcelona Clinic liver cancer stage B(BCLC-B)]HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study.Follow-up was until 2014 or patient death.Two groups were defined in the experiment:The experimental group,treated with sorafenib plus TACE,and the control group,treated with standard TACE alone.RESULTS The Kaplan-Meier survival analysis showed that the median overall survival(mOS)of the experimental group was 35.2 mo,while that of the control group was 22.0 mo(P<0.05).Sorafenib plus TACE showed higher incidence rates of rash,hand-foot syndrome(HFS),and hypertension(P<0.05)than TACE treatment alone.CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the mOS of patients compared to TACE treatment alone.The most common toxicities with sorafenib were rash(31.6%),HFS(39.5%)and hypertension(31.6%),but there were no intolerable adverse events.The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification,tumor diameter,and treatment with sorafenib plus TACE compared to TACE alone.